3 Things You Should Know About Early Treatment Intervention for TED

Thyroid eye disease (TED), a rare autoimmune condition, can be sight-threatening, debilitating, and disfiguring, severely impacting patients’ quality of life and daily functioning. Traditional management approaches for TED have centered on immunomodulatory therapy and surgical interventions. In January 2020, the US Food and Drug Administration (FDA) approved teprotumumab, the first therapy specifically indicated for TED. As treatment options evolve, there is an increasing need for a patient-centered, multidisciplinary approach, which is essential to address individual patient needs throughout the disease course.

This PER On Air Ophthalmology Times podcast provides an in-depth review of some of the key highlights from a satellite symposium that took place at the Envision Summit 2025 meeting in February 2025. This unique and engaging activity focuses on the practical aspects of managing patients with thyroid eye disease, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.